

CURRICULUM VITAE
OF
THORSTEINN LOFTSSON

HOME ADDRESS: Sörlaskjól 44
IS-107 Reykjavík
ICELAND
Tel.: +354-552-6319

UNIVERSITY ADDRESS: Faculty of Pharmaceutical Sciences
University of Iceland
Hagi
Hofsvallagata 53
IS-107 Reykjavík
ICELAND

Tel.: +354-525-4464 (Office)/ +354-525-5825 (Lab.)
Fax: +354-525-4071
E-mail: thorstlo@hi.is
Web: www.hi.is/~thorstlo

SPOUSE: Hanna Lilja Guðleifsdóttir

EDUCATION: Hamrahlíð Junior College, Reykjavík, Iceland.
(1966-1970).

University of Iceland, Dept. of Pharmacy (1970-1972).

University of Copenhagen, Faculty of Pharmaceutical Sciences (formerly the Royal Danish School of Pharmacy), Copenhagen, (1972-1975, M.Sc. in Pharmacy (cand. pharm.), June 1975).

University of Kansas, Department of Pharmaceutical Chemistry (1976-1979, M.S. in Pharmaceutical Chemistry, June 1978 and Ph.D. in the same field, November 1979).

EMPLOYMENT: Professor of Physical Pharmacy (1986 to present)
Faculty of Pharmacy
University of Iceland
Reykjavík, ICELAND.

Associate Professor (1983-1985)
Faculty of Pharmacy
University of Iceland
Reykjavík, ICELAND.

Assistant Professor (1979-1983)
Faculty of Pharmacy
University of Iceland
Reykjavík, ICELAND

deCode Genetics (2001-2004)
Reykjavik, ICELAND

Oculus ehf. (2003 to present)
Director
Reykjavik, ICELAND

Adjunct Associate Professor (1980-1987)
Department of Medicinal Chemistry
College of Pharmacy
J. Hillis Miller Health Center, Box 100497
University of Florida, Gainesville,
FL 32610-0497, U.S.A.

Adjunct Professor (1987-1996)
Center for Drug Discovery
College of Pharmacy
J. Hillis Miller Health Center, Box 100497
University of Florida, Gainesville,
FL 32610-0497, U.S.A.

Adjunct Faculty, Center for Drug Discovery,
College of Pharmacy, University of Florida (2006-)

Registered pharmacist since 1975 and worked as pharmacist in
various drugstores from June 1975 to August 1976.

HONORS, FELLOWSHIPS: Fulbright Fellowship, 1976-1979.
NATO Awards 1978 and 1980.
Member of the Scientific Advisory Board of Pharmatec, Inc., Alachua, Florida (1983-1992).
Faculty Research Award, 1992. Faculty of Medicine,
University of Iceland.
The Nagai Foundation Tokyo, International Scholarship 1998.
Elected to Fellowship status in the American Association of Pharmaceutical Scientists (AAPS), 1998.

MEMBERSHIP: American Chemical Society (Division of Medicinal Chemistry).
Icelandic Pharmacists Association.
Icelandic Biochemical Society.
Societas Scientiarum Islandica
Controlled Release Society.
American Association of Pharmaceutical Scientists (AAPS).
AAPS Fellow.
European Federation of Pharmaceutical Science (EUFEPS).

Edit. Boards: European Journal of Pharmaceutical Sciences. Elsevier Science Publishers, Amsterdam, Holland. (Editorial Advisory Board, 1993-1998.)
Drug Stability. Radcliffe Medical Press of Oxford, Oxford, U.K. (Editorial Board, 1995-1998)
International Journal of Pharmaceutics. Elsevier Science Publishers, Amsterdam, Holland (Editorial Board, from 1998).
Die Pharmazie. GOVI-Verlag, Pharmazeutischer Verlag GmbH, Eschborn, Germany (Editorial Board, from 2000).
Journal of Drug Delivery Science and Technology (formerly STP Pharma Sciences). Editions de Santé, Paris, France (Editorial Board, from 2002).
Journal of Pharmacy and Pharmacology. Pharmaceutical Press, UK (Editorial Board, from 2004).
Journal of Pharmaceutical Sciences, John Wiley & Sons, USA (Editorial Advisory Board, from 1.1.2005 - 31.12.2010).

PUBLICATIONS:

1. T. Loftsson, „*Evaluation of Methylthiomethyl, Methylsulfinyl-methyl and Methylsulfonylmethyl 2-Acetoxybenzoates as Prodrug Forms of Aspirin and Study of the Chemistry of these Compounds and Related Compounds both in vitro and in vivo*,“ University of Kansas, 1979 (Ph.D. Thesis).
2. T. Loftsson, J. Kaminski and N. Bodor, „Improved delivery through biological membranes VIII. Design, synthesis and *in vivo* testing of true prodrugs of aspirin,“ *J. Pharm. Sci.*, 70, 743-749 (1981).
3. T. Loftsson and N. Bodor, „Improved delivery through biological membranes IX. The kinetics and mechanism of hydrolysis of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs,“ *J. Pharm. Sci.*, 70, 750-755 (1981).
4. T. Loftsson and N. Bodor, „Improved delivery through biological membranes X. Percutaneous absorption and metabolism of the methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs“, *J. Pharm. Sci.*, 70, 756-758 (1981).
5. T. Loftsson, „Þróun lyfja gegn illkynja sjúkdómum“, *Tímarit um lyfjafræði*, 16, 20-22 (1981).
6. T. Loftsson, „Experimental and theoretical model for studying simultaneous transport and metabolism of drugs in excised skin“, *Arch. Pharm. Chemi., Sci. Ed.* 10,17-24 (1982).
7. T. Loftsson and N. Bodor, „Synthesis and hydrolysis of some pivaloyloxymethyl and pivaloyl derivatives of phenolic compounds“, *Arch Pharm. Chemi., Sci. Ed.* 10, 104-110 (1982).
8. T. Loftsson, „Hönnun á nýjum lyfjum“, *Tímarit um lyfjafræði* 17(1), 27-32 (1982).
9. T. Loftsson, „Upplýsingagjöf“, *Tímarit um lyfjafræði* 18(1), 13-14 (1983).
10. N. Bodor, Y. Oshiro, T. Loftsson, M. Katovich and W. Caldwell, „Soft drugs VI. The application of the inactive metabolite approach for design of soft β -blockers“, *Pharm. Res.*, 1, 120-125 (1984).
11. T. Loftsson, M. Matsuo, R.W. Caldwell, N. Gildersleeve and N. Bodor, „Synthesis and evaluation of novel lidocaine sulfur analogs,“ *Int. J. Pharm.*, 22, 345-355 (1984).
12. T. Loftsson, „Frásog lyfja í húð“, *Tímarit um lyfjafræði*, 20(1), 24-28 (1985).
13. T. Loftsson, „The effect of ionization on partition coefficients and topical delivery“, *Acta Pharm. Suec.* 22, 209-214 (1985).
14. N. Bodor and T. Loftsson, „Novel chemical approaches for sustained drug delivery“. In „Controlled drug delivery. Fundamentals and applications.“ (J.R. Robinson and V. H. L. Lee, Eds.), Marcel Dekker Inc., New York, 1987, Chapter 8, pp. 337-371.
15. T. Loftsson, N. Gildersleeve and N. Bodor, „The effect of vehicle additives on the transdermal delivery of nitroglycerin“, *Pharm. Res.* 4, 436-437 (1987).

16. K.H. Rand, I. Raad, A. El Koussi, H.J. Houck, W. Brey, J. Rocca, T. Loftsson and N. Bodor, „Trifluorothymidine: Potential non-invasive diagnosis of herpes simplex infection using ^{19}F nuclear magnetic resonance in a murine hepatitis model“, *J. Virol. Methods*, 18, 257-270 (1987).
17. T. Loftsson, „Lyf við gelgjubólum“, *Mixtúra, blað lyfjafræðinema*, 28-29 (1987).
18. M.E. Brewster, K. S. Estes, T. Loftsson, R. Perchalski, H. Derendorf, G. Mullersman and N. Bodor, „Improved delivery through biological membranes XXXI: Solubilization and stabilization of an estradiol chemical delivery system by modified β -cyclodextrins“, *J. Pharm. Sci.*, 77, 981-985 (1988).
19. M.E. Brewster, T. Loftsson, K.S. Estes, G. Mullersman, H. Derendorf and N. Bodor, „Water soluble complexes of a brain-targeted drug delivery system“. In „Proceedings of the Fourth International Symposium on Cyclodextrins“ (O. Huber and J. Szejtli, Eds.), Kluwer Academic Publishers, W.-Germany, 1988, pp. 399-405.
20. T. Loftsson, N. Gildersleeve, R. Soliman and N. Bodor, „Effect of oleic acid on diffusion of drugs through hairless mouse skin“, *Acta Pharm. Nordica*, 1, 17-22 (1989).
21. T. Loftsson „Rannsóknir í lyfjafræði lyfsala“, *Tímarit um lyfjafræði*, 24(1), 21-26 (1989).
22. T. Loftsson and N. Bodor, „Effects of 2-hydroxypropyl- β -cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17β -estradiol“, *Acta Pharm. Nordica*, 1, 185-194 (1989).
23. T. Loftsson, G. Somogyi and N. Bodor, „Effect of choline esters and oleic acid on the penetration of acyclovir, estradiol, hydrocortisone, nitroglycerin retinoic acid and trifluorothymidine across hairless mouse skin in vitro“, *Acta Pharm. Nordica*, 1, 279-286 (1989).
24. T. Loftsson, S. Björnsdóttir, G. Pálsdóttir and N. Bodor, „The effects of 2-hydroxypropyl- β -cyclodextrin on the solubility and stability of chlorambucil and melphalan in aqueous solutions“, *Int. J. Pharm.*, 57, 63-72 (1989).
25. E. Pop, T. Loftsson and N. Bodor, „Novel central nervous system targeted semisynthetic penicillins“, *Drug Design Delivery*, 5, 221-237 (1990).
26. N. Bodor and T. Loftsson, „The effects of phosphine oxides on transdermal delivery“, *Acta Pharm. Nord.* 2, 123-126 (1990).
27. T. Loftsson, B.J. Ólafsdóttir and H. Friðriksdóttir, „Comparative study on inclusion complexation of acetylsalicylic acid, cholecalciferol and melphalan with β - and γ -cyclodextrin and some of their derivatives“, *Acta Pharm. Nord.*, 2, 303-312 (1990).
28. T. Loftsson and H. Friðriksdóttir, „Degradation of lomustine (CCNU) in aqueous solutions“, *Int. J. Pharm.* 62, 243-247 (1990).
29. T. Loftsson, B.J. Ólafsdóttir and N. Bodor, „The effect of cyclodextrins on transdermal delivery of drugs“. *Eur. J. Pharm. Biopharm.* 37, 30-33 (1991).

30. T. Loftsson and B. J. Ólafsdóttir, „The effect of 2-hydroxypropyl- β -cyclodextrin on simultaneous dissolution and degradation of chlorambucil“. *Int. J. Pharm.* 66, 289-292 (1990).
31. T. Loftsson, M.E. Brewster, H. Derendorf and N. Bodor, „2-Hydroxypropyl- β -cyclodextrin: Properties and usage in pharmaceutical formulations“, *Pharmazeutische Zeitung, Wissenschaftsausgabe*, 4/136 (1), 5-10 (1991).
32. K. Raghavan, T. Loftsson, M. E. Brewster and N. Bodor, „Improved delivery through biological membranes XLV: Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery systems“, *Pharm. Res.* 9, 743-749 (1992).
33. E. Pop, T. Loftsson and N. Bodor, „Solubilization and stabilization of a benzylpenicillin chemical delivery system by 2-hydroxypropyl- β -cyclodextrin“, *Pharm. Res.*, 8, 1044-1049 (1991).
34. T. Loftsson and B.J. Ólafsdóttir, „The cyclodextrin-accelerated degradation of β -lactam antibiotics in aqueous solutions“, *Int. J. Pharm.*, 67, R5-R7 (1991).
35. T. Loftsson and H. Friðriksdóttir, „Stabilizing effect of tris(hydroxymethyl)aminomethane (TRIS) on N-nitrosoureas in aqueous solutions“, *J. Pharm. Sci.*, 81, 197-198 (1992).
36. T. Loftsson, H. Friðriksdóttir, B. J. Ólafsdóttir and Ö. Guðmundsson, „Solubilization and stabilization of drugs through cyclodextrin complexation“, *Acta Pharm. Nord.*, 3, 215-217 (1991).
37. Thorsteinn Loftsson, „Forðaplástrar“, *Mixtúra, blað lyfjafræðinema*, 5, 21-22 (1991).
38. N. Bodor, T. Loftsson and W.-M. Wu, „Metabolism, distribution and transdermal permeation of a soft corticosteroid, loteprednol etabonate“, *Pharm. Res.* 9(10), 1275-78 (1992).
39. M.E. Brewster, T. Loftsson, K.S. Estes, J.-L. Lin, H. Friðriksdóttir and N. Bodor, „Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride“, *Int. J. Pharm.* 79, 289-299 (1992).
40. M.E. Brewster, T. Loftsson, J. Baldvinsdóttir and N. Bodor, „Stabilization of aspartame by cyclodextrins“, *Int. J. Pharm.* 75, R5-R8 (1991).
41. T. Loftsson, B.J. Ólafsdóttir and J. Baldvinsdóttir, „Estramustine: Hydrolysis, solubilization, and stabilization in aqueous solutions“, *Int. J. Pharm.*, 79, 107-112 (1992).
42. T. Loftsson, T. Kristmundsdóttir, K. Ingvarsdóttir, B.J. Ólafsdóttir and J. Baldvinsdóttir, „Preparation and physical evaluation of microcapsules of hydrophilic drug-cyclodextrin complexes“. *Journal of Microencapsulation* 9, 375-382 (1992).
43. T. Loftsson, Ó. Stefánsdóttir, H. Friðriksdóttir and Ö. Guðmundsson, „Interactions between preservatives and 2-hydroxypropyl- β -cyclodextrin“. *Drug Dev. Indust. Pharm.* 18(13), 1477-1484 (1992).
44. T. Loftsson, T. Kristmundsdóttir, K. Ingvarsdóttir, J. Baldvinsdóttir and B.J. Ólafsdóttir, „Microcapsules of hydrophilic drug-cyclodextrin complexes“. *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.*, 19, 359-360(1992).

45. T. Loftsson and J. Baldvinsdóttir, „Degradation of tauromustine (TCNU) in aqueous solutions“. *Acta Pharm. Nord.*, 4, 129-132 (1992).
46. T. Loftsson and N. Bodor, „The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids“. *Adv. Drug Deliv. Rev.*, 14, 293-299 (1994).
47. T. Loftsson, T. Kristmundsdóttir, K. Ingvarsdóttir, J. Baldvinsdóttir and B. J. Ólafsdóttir, „Microcapsules of drug-cyclodextrin complexes“. *Minutes of the 6th Int. Symp. on Cyclodextrins* (Chicago, 21/24 April 1992), A.R. Hedges (Ed.), Editions de Santé, Paris, 1992, pp. 456-459.
48. T. Loftsson and J. Baldvinsdóttir, „The stability of aspartame in aqueous solutions“. *Acta Pharm. Nord.*, 4, 329-330 (1992).
49. T. Loftsson, B.J. Ólafsdóttir and H. Friðriksdóttir, „Cyclodextrin complexation of NSAIDs: Physicochemical characteristics“, *Eur. J. Pharm. Sci.*, 1, 95-101 (1993).
50. T. Loftsson and T. Kristmundsdóttir, „Microcapsules containing water-soluble cyclodextrin inclusion complexes of water-insoluble drugs“, Chapter 11, In *Polymer Delivery Systems* (M. El-Nokaly, D. Piatt and B. Charpentier, Eds.), ACS Symposium Series 520, American Chemical Society; Washington, DC, 1993, pp. 168-189.
51. Thorsteinn Loftsson, „Nýjar aðferðir til að hafa áhrif á frásog og dreifingu lyfja“, *Læknablaðið*, 79, 95-105 (1993).
52. T. Loftsson, H. Friðriksdóttir, S. Thórisdóttir, E. Stefánsson, A.M. Sigurðardóttir, Ö. Guðmundsson and T. Sigthórsson, „2-Hydroxypropyl- β -cyclodextrin in topical carbonic anhydrase inhibitor formulations“, *Eur. J. Pharm. Sci.*, 1, 175-180 (1994).
53. T. Loftsson, J. Baldvinsdóttir and A.M. Sigurðardóttir, „The effect of cyclodextrins on the solubility and stability of medroxyprogesterone acetate and megestrol acetate in aqueous solution“, *Int. J. Pharm.*, 98, 225-230 (1993).
54. Thórdís Kristmundsdóttir, Thorsteinn Loftsson, W. Peter Holbrook, Kristín Ingvarsdóttir and Hafrún Friðriksdóttir, „Hönnun og klínískt mat á hýdrókortisón lausn til meðhöndlunar á bólgusjúkdómum í munnholi“, *Mixtúra blað lyfjafræðinema*, 7, 5-6 (1993).
55. T. Loftsson, H. Friðriksdóttir, G. Ingvarsdóttir, B. Jónsdóttir and A.M. Sigurðardóttir, „The influence of 2-hydroxypropyl- β -cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone“, *Drug Dev. Ind. Pharm.*, 20, 1699-1708 (1994).
56. J.H. Ólafsson, T. Loftsson and H. Friðriksdóttir, „Topical delivery of acetazolamide for psoriasis“, *Acta Derm. Venereol.*, 73, 467 (1993).
57. T. Loftsson, H. Friðriksdóttir, S. Thórisdóttir and E. Stefánsson, „The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl- β -cyclodextrin formulations“, *Int. J. Pharm.*, 104, 181-184 (1994).
58. T. Loftsson, H. Friðriksdóttir, E. Stefánsson, S. Thórisdóttir, Ö. Guðmundsson and T. Sigthórsson, „Topically effective ocular hypotensive acetazolamide and ethoxylamide formulations“, *J. Pharm Pharmacol.*, 46, 503-504 (1994).

59. T. Loftsson and N. Bodor, „The effect of cyclodextrins on percutaneous transport of drugs“, Chapter 11. In *Percutaneous Penetration Enhancers*, E. W. Smith and H. I. Maibach, CRC Press, 1995, pp. 335-342.
60. T. Loftsson and H. R. Jóhannesson, „The influence of cyclodextrins on the stability of cephalothin and aztreonam in aqueous solutions“ *Die Pharmazie*, 49, 292-293 (1994).
61. T. Loftsson, B. Jónsdóttir, J. Baldvinsdóttir and H. Friðriksdóttir, „Effect of cyclodextrins on the degradation of cortisone acetate, estradiol benzoate and prednicarbate in aqueous solution“, *s.t.p. pharma sciences*, 4, 354-358 (1994).
62. J.D. Cleary, R. Gunnarsdóttir, T. Loftsson and E. Magnússon, „Pharmacy in Iceland“, *The Annals of Pharmacotherapy*, 28, 112-115 (1994).
63. Thórdís Kristmundsdóttir and Thorsteinn Loftsson. „Kynning á rannsóknum í lyfjafræði. Míkróhúðun vatnsleysanlegra cýklódextrín-flétta.“ *Tímarit um lyfjafræði*, 28(2) 4-8 (1993).
64. T. Loftsson, H. Friðriksdóttir, A.M. Sigurðardóttir and H. Ueda, „The effect of water-soluble polymers on drug-cyclodextrin complexation“, *Int. J. Pharm.*, 110, 169-177 (1994).
65. T. Loftsson and A.M. Sigurðardóttir, „The effect of polyvinylpyrrolidone and hydroxypropyl methylcellulose on HP β CD complexation of hydrocortisone and its permeability through hairless mouse skin“, *Eur. J. Pharm. Sci.*, 2, 297-301 (1994).
66. T. Loftsson, „The effects of cyclodextrins on the chemical stability of drugs in aqueous solutions.“ *Drug Stability*, 1, 22-33 (1995).
67. T. Loftsson, J. Pitha, T. Kristmundsdóttir, T. Utsuki, A. Olivi and H. Brem, „Microencapsulation of a carboplatin-HP α CD complex“. In *Proceedings of the 7th International Cyclodextrins Symposium*, (T. Osa et al., Eds.), Business Center for Academic Societies Japan, Tokyo 1994, pp. 423-426.
68. T. Loftsson, E. Stefánsson, H. Friðriksdóttir, S. Thórisdóttir, J.K. Kristinsson and G. Guðmundsson, „Topical acetazolamide-HP β CD eye drop solution“. In *Proceedings of the 7th International Cyclodextrins Symposium*, (T. Osa et al., Eds.), Business Center for Academic Societies Japan, Tokyo 1994, pp. 447-450.
69. T. Loftsson, E. Stefánsson, S. Thórisdóttir, H. Friðriksdóttir and J.K. Kristinsson, „Dexamethasone-HP β CD-polymer co-complex in eye drops“. In *Proceedings of the 7th International Cyclodextrins Symposium*, (T. Osa et al., Eds.), Business Center for Academic Societies Japan, Tokyo 1994, pp. 451-454.
70. T. Loftsson, H. Friðriksdóttir and A.M. Sigurðardóttir, „The effect of polymers on cyclodextrin complexation“. In *Proceedings of the 7th International Cyclodextrins Symposium*, (T. Osa et al., Eds.), Business Center for Academic Societies Japan, Tokyo 1994, pp. 218-221.
71. T. Loftsson, Thórunn K. Guðmundsdóttir, Hafrún Friðriksdóttir, Anna M. Sigurðardóttir, J. Thorkelsson, G. Guðmundsson and B. Hjaltason, „Fatty acids from cod-liver oil as skin penetration enhancers“, *Pharmazie*, 50, 188-190 (1995).

72. T. Loftsson, A.M. Sigurðardóttir and J.H. Ólafsson, „Improved acitretine delivery through hairless mouse skin by cyclodextrin complexation“, *Int. J. Pharm.*, 115, 255-258 (1995).
73. T. Kristmundsdóttir, T. Loftsson and W.P. Holbrook, „Formulation and clinical evaluation of a hydrocortisone solution for the treatment of oral disease“, *Int. J. Pharm.*, 139, 63-68 (1996).
74. M.E. Brewster, T. Loftsson, S. Amselem, D. Friedman, A. Yogev, W.R. Anderson, D.O. Helton, A. Dinculescu, N. Bodor and E. Pop, „Formulation development for a zidovudine chemical delivery system. 1. Parenteral dosage forms“, *Int. J. Pharm.*, 125, 17-30 (1995).
75. S. Amselem, D. Friedman, A. Yogev, W.R. Anderson, D.O. Helton, T. Loftsson, N. Bodor, E. Pop and M. Brewster, „Formulation development for a zidovudine chemical delivery system. 2. Towards oral and non-parenteral dosage forms“, *Int. J. Pharm.*, 125, 31-43 (1995).
76. T. Loftsson, E. Stefánsson, J.K. Kristinsson, H. Friðriksdóttir, T. Sverrisson, G. Guðmundsdóttir and S. Thórisdóttir, „Topically effective acetazolamide eye-drop solution in man“, *Pharm. Sci.*, 6, 277-279 (1996).
77. A. M. Sigurðardóttir and T. Loftsson, „The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin“ *Int. J. Pharm.*, 126, 73-78 (1995).
78. T. Loftsson, T.K. Guðmundsdóttir and H. Friðriksdóttir, „The influence of water-soluble polymers and pH on hydroxypropyl- β -cyclodextrin complexation of drugs“, *Drug Devel. Ind. Pharm.*, 22, 401-405 (1996).
79. T. Loftsson, H. Friðriksdóttir and T.K. Guðmundsdóttir, „The effect of water-soluble polymers on aqueous solubility of drugs“ *Int. J. Pharm.*, 127, 293-296 (1996).
80. T. Utsuki, H. Brem, J. Pitha, T. Loftsson, T. Kristmundsdóttir, B.M. Tyler and A. Olivi, „Protection of anticancer effects of microencapsulated carboplatin by hydroxypropyl- β -cyclodextrin“, *Journal of Controlled Release*, 40, 251-260 (1996).
81. M.E. Brewster, W.R. Anderson, T. Loftsson, M.-J. H., N. Bodor and E. Pop, „Preparation and anesthetic properties of 2-hydroxypropyl- β -cyclodextrin complexes of pregnanolone and pregnenolone“, *J. Pharm. Sci.*, 84, 1154-1159 (1995).
82. T. Loftsson and E. Stefánsson, „Cyclodextrin Based Drug Delivery System“, University of Iceland, Reykjavik, January 1995.
83. H. Friðriksdóttir, T. Loftsson, J.A. Guðmundsson, G.J. Bjarnason, M. Kjeld and Tanja Thorsteinsson, „Design and in vivo testing of 17 β -estradiol-HP β CD sublingual tablets“, *Pharmazie*, 51, 39-42 (1996).
84. T. Loftsson and E. Stefánsson, „Effect of cyclodextrins on topical drug delivery to the eye“, *Drug Devel. Ind. Pharm.*, 23, 473-481 (1997).
85. T. Loftsson, H. Friðriksdóttir and T.K. Guðmundsdóttir, „Fatty acids as skin penetration enhancers“, *Proceedings of the "18th Nordic Lipid Symposium"*, G. G. Haraldsson, S. Guðbjarnason and G. Lambertsen, Eds., Reykjavík, 18.-21 June, 1995. pp. 243-247.

86. J. K. Kristinsson, H. Friðriksdóttir, S. Thórisdóttir, A. M. Sigurðardóttir, E. Stefánsson and T. Loftsson, „Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans“, *Investigative Ophthalmology and Visual Science*, 37(6), 1199-1203 (1996).
87. T. Loftsson, E. Stefánsson, H. Friðriksdóttir and J.K. Kristinsson, „Novel CD-based drug delivery system“, *Proceedings of the 8th International Cyclodextrins Symposium*, (J. Szejtli and L. Sente, Eds.), Kluwer Academic Publishers, Dordrecht, 1996, pp. 407-412.
88. E. Stefánsson, S. Thórisdóttir, Ó.G. Guðmundsson, T. Loftsson, H. Friðriksdóttir and J.K. Kristinsson, „HP β CD in eye drops: evaluation of artificial tear-drops in human patients“, *Proceedings of the 8th International Cyclodextrins Symposium*, (J. Szejtli and L. Sente, Eds.), Kluwer Academic Publishers, Dordrecht, 1996, pp. 391-394.
89. M. Másson, T. Loftsson, H. Friðriksdóttir and D.S. Petersen „Complexation of drug compounds with ionic and non-ionic cyclodextrins“, *Proceedings of the 8th International Cyclodextrins Symposium*, (J. Szejtli and L. Sente, Eds.), Kluwer Academic Publishers, Dordrecht, 1996, pp. 365-368.
90. T. Loftsson and A.M. Sigurðardóttir, „Cyclodextrins as skin penetration enhancers“, *Proceedings of the 8th International Cyclodextrins Symposium*, (J. Szejtli and L. Sente, Eds.), Kluwer Academic Publishers, Dordrecht, 1996, pp. 403-406.
91. H. Friðriksdóttir and T. Loftsson, „Solubilization of β -cyclodextrin“, *Proceedings of the 8th International Cyclodextrins Symposium*, (J. Szejtli and L. Sente, Eds.), Kluwer Academic Publishers, Dordrecht, 1996, pp. 373-376.
92. M.E. Brewster, W.R. Anderson, T. Loftsson, N. Bodor and E. Pop, „Effect of 2-hydroxypropyl- β -cyclodextrin complexes of the neurosteroids, alfaxalone, pregnanolone and pregnolone, on various convulsant stimuli in the mouse“, *Proceedings of the 8th International Cyclodextrins Symposium*, (J. Szejtli and L. Sente, Eds.), Kluwer Academic Publishers, Dordrecht, 1996, pp. 511-514.
93. T. Loftsson and M.E. Brewster, „Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization“, *J. Pharm. Sci.* 85(10), 1017-1025 (1996).
94. W.P. Holbrook, T. Kristmundsdóttir and T. Loftsson, "Aqueous hydrocortisone mouthwash solution: clinical evaluation“, *Acta Odontologica Scandinavica*, 56, 157-160, (1998).
95. T. Loftsson, A.M. Sigurðardóttir and H. Friðriksdóttir, „Effects of cyclodextrins and polymers on transdermal drug delivery“, *Proceed. Intern. Control. Rel. Bioact. Mater.*, No. 23, Controlled Release Society Inc., Deerfield (USA), p. 194-195 (1996).
96. T. Loftsson, E. Stefánsson, H. Friðriksdóttir and J.K. Kristinsson, „Effects of cyclodextrins and polymers on topical drug delivery to the eye - Evaluation in humans“, *Proceed. Intern. Control. Rel. Bioact. Mater.*, No. 23, Controlled Release Society Inc., Deerfield (USA), p. 453-454 (1996).
97. T. Loftsson and D.S. Petersen, „Cyclodextrin solubilization of water-insoluble drugs: calcipotriol and EB-1089“, *Pharmazie*, 52, 783-785 (1997).

98. Hafrún Friðriksdóttir and Thorsteinn Loftsson, „Áhrif fjölliða á cyklódextrínfléttun lyfja og aðgengi í gegnum lífrænar himnur“, *Tímarit um lyfjafræði*, 31(3), 10-16 (1996).
99. T. Loftsson, D.S. Petersen, F. Le Goffic and J.H. Ólafsson, „Unsaturated glycerol monoethers as novel skin penetration enhancers“, *Pharmazie*, 52, 463-465 (1997).
100. T. Loftsson and M.E. Brewster, „Cyclodextrins as pharmaceutical excipients“, *Pharmaceutical Technology - Europe*, 9(5), 26-34 (1997).
101. M.E. Brewster and T. Loftsson, „Complexation - Use of cyclodextrins to improve pharmaceutical properties of intramuscular formulations“, in „*Injectable drug development. Techniques to reduce pain and irritation*“, (P. Gupta and G. Brazeau, Eds.), Interpharm Press, Denver, USA, pp. 307-336 (1999).
102. H. Friðriksdóttir, T. Loftsson and E. Stefánsson, „Formulation and testing of methazolamide cyclodextrin eye drop solutions“, *J. Control. Rel.*, 44, 95-99 (1997).
103. T. Loftsson and H. Friðriksdóttir, „The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β -cyclodextrin“, *Int. J. Pharm.* 163, 115-121 (1998).
104. T. Loftsson, T. Gunnarsdóttir, L.M. Magnúsdóttir, H. Friðriksdóttir, T.K. Guðmundsdóttir, J.H. Ólafsson, G.G. Haraldsson, G. Guðmundsson and B. Hjaltason, „Effects of various marine lipids on transdermal drug delivery - *in vitro* evaluation“, *Bollettino Chimico Farmaceutico*, 136(10), 640-645 (1997).
105. T. Loftsson and D.S. Petersen, „Cyclodextrin solubilization of ETH-615, a zwitterionic drug“, *Drug Devel. Ind. Pharm.*, 24(4), 365-370 (1998).
106. W.P. Holbrook, Thórdís Kristmundsdóttir and Thorsteinn Loftsson, „Klínískt mat á hýdrókortisón-munnskoli (Dexocort®)“, *Mixtúra*, 11, 4-5 (1997).
107. T. Loftsson and J.H. Ólafsson, „Cyclodextrins: new drug delivery systems in dermatology“, *Int. J. Dermatol.*, 37, 241-246 (1998).
108. T. Loftsson, M. Másson, H.H. Sigurðsson, P. Magnússon and F. La Goffic, „Cyclodextrins as co-enhancers in dermal and transdermal drug delivery“, *Pharmazie*, 53, 137-139 (1998).
109. K. Tsutsumi, Y. Obata, K. Takayama, T. Loftsson and T. Nagai, "Effect of cod-liver oil extract on the buccal permeation of ergotamine tartrate", *Drug Devel. Ind. Pharm.*, 24, 757-762 (1998).
110. M. Másson, T. Loftsson, S. Jónsdóttir, H. Friðriksdóttir and D.S. Petersen, „Stabilization of ionic drugs through complexation with non-ionic and ionic cyclodextrins“, *Int. J. Pharm.* 164, 45-55 (1998).
111. T. Loftsson, H. Thormar, J.H. Ólafsson, T.M. Gunnarsdóttir, B. Hjaltason and G. Guðmundsson, „Fatty acid extract from cod-liver oil: activity against herpes simplex virus and enhancement of transdermal delivery of acyclovir“, *Pharm. Pharmacol. Commun.*, 4, 287-291 (1998).
112. T. Loftsson, M. Másson, J.F. Sigurjónsdóttir and H. Friðriksdóttir, „Enhanced complexation efficacy of cyclodextrins“, *Proceedings of the 17th Pharmaceutical Technology Conference and Exhibition*, Dublin, 24-26 March 1998, pp. 264-277.

113. T. Loftsson, M. Masson and E. Stefansson, „Cyclodextrins as Permeation enhancers“, *Proceedings of the 17th Pharmaceutical Technology Conference and Exhibition*, Volume 2, Dublin, 24-26 March 1998, pp. 313-324.
114. T. Loftsson, J.H. Olafsson, F. Le Goffic and B. Hjaltason, „Marine lipids as skin penetration enhancers“, *Proceedings of the 17th Pharmaceutical Technology Conference and Exhibition*, Volume 3, Dublin, 24-26 March 1998, pp. 58-70.
115. M. Masson, J. Pitha and T. Loftsson, „Synthesis of cyclodextrin glycerol ethers and investigation of their binding properties with drugs“, *Journal of Inclusion Phenomena*, 33, 459-467 (1999).
116. K.M. Saari, H. Jyrkko, H. Seppa, T. Loftsson and E. Stefansson, „Acute and chronic postoperative inflammatory reactions after cataract extraction and intraocular lens implantation“. In (S. Ohno, K. Aoki, M. Usui and E. Uchio, Eds.) *Uveitis Today*, pp. 99-102, 1998.
117. J. Savolainen, K. Jarvinen, H. Taipale, P. Jarho, T. Loftsson and T. Jarvinen, „Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid oral dosage forms“, *Pharm. Res.* 15(11), 1696-1701 (1998).
118. T. Loftsson, „Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers“ *Pharmazie*, 53, 733-740 (1998).
119. T. Loftsson, M. Masson and J. F. Sigurjonsdottir, „Enhanced complexation efficacy of cyclodextrins“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 257-260 (1999).
120. T. Loftsson and M. Masson, „Complexation properties of β -cyclodextrin sulfobutylether sodium salt“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 359-362 (1999).
121. M. Masson and T. Loftsson, „Evaluation of degradation studies performed in aqueous cyclodextrin solutions“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 265-268 (1999).
122. M. Masson, J. Pitha and T. Loftsson, „Synthesis of cyclodextrin glycerol ethers and investigation of their binding properties“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 109-112 (1999).
123. J. Savolainen, K. Jarvinen, H. Taipale, P. Jarho, T. Loftsson and T. Jarvinen, „Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid dosage forms“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 261-264 (1999).

124. J.F. Sigurjónsdóttir, M. Másson and T. Loftsson, „Influence of cyclodextrins on the chemical stability of salmon calcitonin in aqueous solutions“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 355-358 (1999).
125. M. Másson, T. Loftsson and E. Stefánsson, „How do cyclodextrins enhance drug permeability through biological membranes?“, J.J. Torres-Labandeira and J.L. Vila-Jato (Eds.): *Proceedings of the Ninth International Symposium on Cyclodextrins*, Santiago de Compostela, Spain, May 31 – June 3, 1998, Kluwer Academic Publishers, Dordrecht, pp. 363-366 (1999).
126. T. Loftsson and T. Järvinen, „Cyclodextrins in ophthalmic drug delivery“, *Adv. Drug Delivery Reviews*, 36, 59-79 (1999).
127. M. Másson, T. Loftsson, G. Másson and E. Stefánsson, „Cyclodextrins as permeation enhancers: some theoretical evaluations and *in vitro* testing“, *J. Controlled Release*, 59, 107-118, 1999.
128. K. Tsutsumi, Y. Obata, K. Takayama, T. Loftsson and T. Nagai, „Effect of cod-liver oil extract on the buccal permeation of ergotamine tartrate“, *Proceed. Intern. Control. Rel. Bioact. Mater.*, No. 25, Controlled Release Society Inc., Deerfield (USA), p. 826-827 (1998).
129. K. Tsutsumi, Y. Obata, K. Takayama, T. Loftsson and T. Nagai, „Effect of the cod-liver oil extract on the buccal permeation of ionized and nonionized forms of ergotamine using the keratinized epithelial-free membrane of hamster cheek pouch mucosa“, *Int. J. Pharm.*, 174, 151-156 (1998).
130. T. Loftsson, M. Másson and J. F. Sigurjónsdóttir, „Methods to enhance the complexation efficiency of cyclodextrins“, *s.t.p. pharm. sci.* 9, 237-242 (1999).
131. T. Thorsteinsson, M. Másson, T. Loftsson, G.G. Haraldsson and E. Stefánsson, „Diacyl glyceryl ester prodrugs for slow release in the skin: synthesis and *in vitro* degradation and absorption studies for naproxen derivatives“, *Pharmazie*, 54, 831-836 (1999).
132. T. Loftsson, N. Leeves, B. Björnsdóttir, L. Duffy and M. Másson, „The effect of cyclodextrins and polymers on triclosan availability and substantivity in toothpastes *in vivo*“, *J. Pharm. Sci.*, 88, 1254-1258 (1999).
133. M. Másson and T. Loftsson, „Drug-cyclodextrin complexation in the presence of water-soluble polymers: enhanced solubility and percutaneous transport“. In *Polysaccharide Applications. Cosmetics and Pharmaceuticals*, M. A. El-Nokaly and H. A. Soini (Eds.), ACS Symposium Series No. 737, American Chemical Society, Washington DC, 1999, pp. 24-45.
134. R. J. Little, N. Bodor and T. Loftsson, „Soft drugs based on hydrocortisone. The inactive metabolite approach and its application to steroidal antiinflammatory agents“, *Pharm. Res.* 16, 961-967 (1999).

135. J. F. Sigurjónsdóttir, T. Loftsson and M. Másson, „Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution“, *Int. J. Pharm.* 186, 207-215 (1999).
136. T. Thorsteinsson, M. Masson and T. Loftsson, „Dermal delivery of ETH-615, a zwitterionic drug“, *Drug Devel. Ind. Pharm.* 26, 709-714 (2000).
137. K. M. Saari, L. H. Nelimarkka, V. Ahola, T. Loftsson and E. Stefánsson, „Comparison of 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postoperative inflammation“, *Graefe's Archive for Clinical and Experimental Ophthalmology*, 244, 620-626 (2006).
138. T. Loftsson, „Pharmaceutical applications of β -cyclodextrin“, *Pharm. Technol. Europe*, 11(10), 20-32 (1999) and *Pharm. Technol.* 23(12), 40-50 (1999).
139. M. Másson, T. Thorsteinsson, T. H. Sigurðsson and T. Loftsson, „Lipophilic metronidazole derivatives and their absorption through hairless mouse skin“, *Pharmazie*, 55, 369-371 (2000).
140. M. Másson, T. Loftsson and G.G. Haraldsson, „Marine lipids for prodrugs, soft compounds and other pharmaceutical applications“, *Pharmazie*, 55, 172-177 (2000).
141. E. Guðmundsdóttir, E. Stefánsson, G. Bjarnadóttir, J.F. Sigurjónsdóttir, G. Guðmundsdóttir, M. Másson and T. Loftsson, „Methazolamide 1% in cyclodextrin solution lowers IOP in ocular hypertensive humans“, *Inv. Ophthalmol. Vis. Sci.*, 41(11), 3552-3554 (2000).
142. T. Loftsson, H. Guðmundsdóttir, J.F. Sigurjónsdóttir, H.H. Sigurðsson, S.D. Sigfússon, M. Másson and E. Stefánsson, „Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray“, *Int. J. Pharm.* 212, 29-40 (2001).
143. H. Gudmundsdottir, J.F. Sigurjonsdottir, O. Fjalldal, H.H. Sigurdsson, S.D. Sigfusson, M. Masson, T. Loftsson and E. Stefansson, „Midazolam solubilized with cyclodextrins: formulation of a nasal spray and preliminary clinical testing“, *Proceedings of the 10th International Cyclodextrin Symposium*, Ann Arbor, Michigan, 21.-24. May 2000.
144. M. Másson, M.J. Niskanen, T. Järvinen and T. Loftsson, „Methodology for measuring the stability of drugs in cyclodextrin solutions and estimating stability in pharmaceutical formulations“, *Proceedings of the 10th International Cyclodextrin Symposium*, Ann Arbor, Michigan, 21.-24. May 2000.
145. E. Gudmundsdottir, E. Thorgeirsson, J.F. Sigurjónsdóttir, E. Stefánsson and T. Loftsson, „Randomly methylated β -cyclodextrin in dexamethasone eye drop solution“, *Proceedings of the 10th International Cyclodextrin Symposium*, Ann Arbor, Michigan, 21.-24. May 2000.
146. T. Loftsson, M. Másson and E. Stefánsson, „The effects of cyclodextrins on drug availability in pharmaceutical formulations“, *Proceedings of the 10th International Cyclodextrin Symposium*, Ann Arbor, Michigan, 21.-24. May 2000.

147. J.F. Sigurjónsdóttir, S. Jónsdóttir, M. Másson and T. Loftsson, „A ¹⁹F-NMR study of cyclodextrin complexation in the presence of water-soluble polymers“, *Proceedings of the 10th International Cyclodextrin Symposium*, Ann Arbor, Michigan, 21.-24. May 2000.
148. T. Loftsson, „Cyclodextrins in skin delivery“, *Cosmetics & Toiletries magazine*, **115**(10), 59-66 (2000).
149. J.F. Sigurjónsdóttir, S. Jónsdóttir, M. Másson and T. Loftsson, „¹⁹F-NMR for the study of cyclodextrin complexes“, *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.*, 27(2000), 698-699, Controlled Release Society, Deerfield, USA.
150. J.F. Sigurjónsdóttir, H. Guðmundsdóttir, H.H. Sigurðsson, S.D. Sigfússon, M. Másson, O. Fjalldal, E. Stefánsson and T. Loftsson, „Formulation and preliminary clinical testing of midazolam-cyclodextrin nasal spray“, *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.*, 27(2000), 700-701, Controlled Release Society, Deerfield, USA.
151. T. Loftsson, „Pharmaceutical application of β-cyclodextrin“, *Cyclodextrin News*, 15, 23-24 (2001).
152. T. Loftsson, M. Másson and H. H. Sigurðsson, „Cyclodextrins and drug permeability through semi-permeable cellophane membranes“, *Int. J. Pharm.*, **232**, 35-43 (2002).
153. T. Loftsson and M. Másson, „Cyclodextrins in topical drug formulations: theory and practice“, *Int. J. Pharm.*, **225**, 15-30 (2001).
154. T. Loftsson, M. Másson, H. H. Sigurdsson, E. Knudsen and A. Magnusdottir, “The effect of HPβCD on hydrocortisone permeability through semi-permeable cellophane membranes“, *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.*, 28(2001), #5146, Controlled Release Society, Deerfield, USA, pp. 439-440.
155. J. F. Sigurjónsdóttir, A. Magnúsdóttir, M. Másson and T. Loftsson, „Do complexes of diflunisal sodium with 2-hydroxypropyl-β-cyclodextrin form micelles in solution?“, *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.*, 28(2001), #5148, Controlled Release Society, Deerfield, USA, pp. 443-444.
156. H. Gudmundsdottir, J.F. Sigurjonsdottir, M. Masson, O. Fjalldal, E. Stefansson and T. Loftsson, „Intranasal administration of midazolam in cyclodextrin based formulation: bioavailability and clinical evaluation in humans“, *Pharmazie* **56**, 963-966 (2001).
157. T. Loftsson, N. Leeves, J.F. Sigurjonsdottir, H.H. Sigurdsson and M. Masson, „Sustained drug delivery system based on a cationic polymer and an anionic drug/cyclodextrin complex“, *Pharmazie* **56**, 746-747 (2001).
158. M. E. Brewster and T. Loftsson, „The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems“, *Pharmazie* **57**, 94-101 (2002).
159. T. Loftsson and E. Stefansson, „Cyclodextrin enhanced topical delivery of corticosteroids to the eye“, *Acta Ophthalmol. Scand.* **80**, 144-150 (2002).

160. K. Tsutsumi, Y. Obata, T. Nagai, T. Loftsson and K. Takayama, „Buccal absorption of ergotamine tartrate using bioadhesive tablet system in guinea pigs“, *Int. J. Pharm.* **238**, 161-170 (2002).
161. H. Hjorth Tønnesen, M. Másson and T. Loftsson, „Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability“, *Int. J. Pharm.* **244**, 127-135 (2002).
162. T. Loftsson, A. Magnúsdóttir, M. Másson and J. F. Sigurjónsdóttir, „Self-association and cyclodextrin solubilization of drugs“, *J. Pharm. Sci.* **91**, 2307-2316 (2002).
163. T. Thorsteinsson, M. Másson, T. Jarvinen, T. Nevalainen and T. Loftsson, „Cycloserine fatty acid derivatives as prodrugs: Synthesis, degradation and in vitro skin permeability“, *Chem. Pharm. Bull.* **50**, 554-557 (2002).
164. Már Másson, Jóhanna F. Sigurjónsdóttir, Sigríður Jónsdóttir, Thorsteinn Loftsson, „Examination of ¹⁹F-NMR as a Tool for Investigation of Drug-Cyclodextrin Complexes“, *Drug Devel. Ind. Pharm.* **29**, 107-112 (2003).
165. T. Loftsson and R. O’Fee, „Cyclodextrin based drug delivery“, *Business Briefing: PharmaTech 2002*, World Markets Research Centre Ltd., London, 2002, pp. 136-140.
166. T. Loftsson, „Cyclodextrins and the biopharmaceutics classification system“, *J. Incl. Phenom. Macroc. Chem.* **44**, 63-67 (2002).
167. A. Magnúsdóttir, M. Másson and T. Loftsson, „Self association and cyclodextrin solubilization of NSAIDs“, *J. Incl. Phenom. Macroc. Chem.* **44**, 213-218 (2002).
168. H. H. Sigurðsson, A. Magnúsdóttir, M. Másson and T. Loftsson, „Effects of cyclodextrins on hydrocortisone permeability through semi-permeable membranes“, *J. Incl. Phenom. Macroc. Chem.* **44**, 163-167 (2002).
169. H. H. Sigurðsson, E. Knudsen, T. Loftsson, N. Leeves, J. F. Sigurjonsdottir and M. Masson, „Mucoadhesive sustained drug delivery system based on cationic polymer and anionic cyclodextrin/triclosan complex“, *J. Incl. Phenom. Macroc. Chem.* **44**, 169-172 (2002).
170. M. Másson, S. D. Sigfússon and T. Loftsson, „Fish skin as model membrane to study transmembrane drug delivery with cyclodextrins“, *J. Incl. Phenom. Macroc. Chem.* **44**, 177-182 (2002).
171. E. Stefánsson and T. Loftsson, „Cyclodextrins in eye drop formulations“, *J. Incl. Phenom. Macroc. Chem.* **44**, 23-27 (2002).
172. T. Thorsteinsson, T. Loftsson and M. Masson, „Soft antibacterial agents“, *Current medicinal Chemistry*, **10**, 1241-1253 (2003).
173. T. Loftsson, S. D. Sigfússon, H. H. Sigurðsson and M. Másson, „The effects of cyclodextrins on topical delivery of hydrocortisone: the aqueous diffusion layer“, *STP Pharma Sci.*, **13**, 125-131 (2003).

174. T. Thorsteinsson, M. Masson, K. G. Kristinsson, M. A. Hajlarsdottir, H. Hilmarsson and T. Loftsson, „Soft antimicrobial agents: synthesis and activity of labile environmental friendly long chain quaternary ammonium compounds”, *J. Med. Chem.*, **46**, 4173-4181 (2003).
175. T. Loftsson, J. A. Guomundsson, R. O. Arnadottir and H. Friðriksdottir, „Sublingual delivery of 17 β -estradiol from cyclodextrin containing tablets”, *Pharmazie*, **58**, 358-359 (2003).
176. T. Loftsson, K. Matthıasson and M. Masson, „The effects of organic salts on cyclodextrin solubilization of drugs”, *Int. J. Pharm.* **262**, 101-107 (2003).
177. T. Loftsson and R. O’Fee, „Cyclodextrin in solid dosage forms”, *Business Briefing: PharmaTech 2003*, World Markets Research Centre Ltd., London, 2003, 176-180.
178. T. Loftsson, H. H. Sigurosson, M. Masson and N. Schipper, „Preparation of solid drug/cyclodextrin complexes of acidic and basic drugs”, *Pharmazie*, **59**, 25-29 (2004).
179. T. Loftsson and M. Masson, „The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs”, *J. Drug Del. Sci. Tech.*, **14**, 35-43 (2004).
180. T. Loftsson, T. Thorsteinsson and M. Masson, „Marine lipids as building blocks for soft quaternary ammonium compounds and their antibacterial activity”, *Pharmazie*, **59**, 360-364 (2004).
181. T. Loftsson, M. Masson and M. E. Brewster, „Self-Association of cyclodextrins and cyclodextrin complexes”, *J. Pharm. Sci.* **93**, 1091-1099 (2004).
182. L. Ribeiro, T. Loftsson, D. Ferreira, and F. Veiga, „Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β -cyclodextrin binary and ternary complexes”, *Chem. Pharm. Bull.*, **51**, 914-922 (2003).
183. M.E. Brewster, T. Loftsson, and N. Bodor, „Applications of chemically modified cyclodextrins: use of hydroxypropyl- β -cyclodextrin as an enabling excipient for brain-targeting, redox-based derivatives of estradiol. A review of preclinical and clinical findings”, *J. Drug Del. Sci. Tech.*, **14**, 21-34 (2004).
184. T. Loftsson, M. E. Brewster and M. Masson, „Role of cyclodextrins in improving oral drug delivery”, *Am. J. Drug Deliv.*, **2**, 261-275 (2004).
185. J. Holappa, T. Nevalainen, J. Savolainen, P. Soininen, M. Elomaa, R. Safin, S. Suvanto, T. Pakkanen, M. Masson, T. Loftsson and T. Jarvinen, „Synthesis and characterization of chitosan N-betainates having various degrees of substitution”, *Macromolecules*, 2784-2789 (2004).
186. T. Loftsson, I. B. Ossurardottir, M. Duan, N. Zhao, T. Thorsteinsson and M. Masson, „Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: effect of ionization and polymers”, *J. Incl. Phenom. Macro. Chem.*, **52**, 109-117 (2005).
187. T. Loftsson, E. Stefansson, H. H. Sigurosson, E. Guomundsdottir, T. Eysteinnsson, „Preparation and in vivo evaluation of aqueous dorzolamide/RM β CD eye drop solutions”, *Minutes (Proceedings) of the 12th International Cyclodextrin Symposium*, Montpellier

- (France), May 16-19, 2004, Editions de Santé, Paris 2004. Page 899-902.
188. T. Loftsson, M. Másson, „Phase-solubility diagrams and stoichiometry of drug/cyclodextrin complexes”, *Minutes (Proceedings) of the 12th International Cyclodextrin Symposium*, Montpellier (France), May 16-19, 2004, Editions de Santé, Paris 2004. Page 409-416.
 189. T. Loftsson, Í. B. Össurardóttir, M. Duan, M. Másson, N. Zhao, „Preparation of triclosan/cyclodextrin complexes and their aggregate formation”, *Minutes (Proceedings) of the 12th International Cyclodextrin Symposium*, Montpellier (France), May 16-19, 2004, Editions de Santé, Paris 2004. Page 311-314.
 190. M. Másson, B. V. Sigurdardóttir, K. Matthíasson, T. Loftsson, „New phase-distribution method to investigate cyclodextrin complexation”, *Minutes (Proceedings) of the 12th International Cyclodextrin Symposium*, Montpellier (France), May 16-19, 2004, Editions de Santé, Paris 2004. Page 423-426.
 191. M. Másson, T. Loftsson, K. Matthíasson, „Cyclodextrin solubilization of drugs enhanced with organic anions and cations”, *Minutes (Proceedings) of the 12th International Cyclodextrin Symposium*, Montpellier (France), May 16-19, 2004, Editions de Santé, Paris 2004. Page 315-318.
 192. M. Másson, T. Loftsson, H. H. Sigurdsson, Nicolaas Schipper, „Reduced formulation bulk of cyclodextrin complexes through addition and subsequent removal of volatile acids or bases”, *Minutes (Proceedings) of the 12th International Cyclodextrin Symposium*, Montpellier (France), May 16-19, 2004, Editions de Santé, Paris 2004. Page 319-322.
 193. T. Järvinen, J. Rautio, M. Masson and T. Loftsson, „Design and pharmaceutical applications of prodrugs”, in S. C. Gad (Ed.) *Drug Discovery Handbook*, John Wiley & Sons, Hoboken (NJ), 2005, pp. 733-796.
 194. H. H. Sigurðsson, E. Stefánsson, E. Guðmundsdóttir, T. Eysteinnsson, M. Thorsteinsdóttir and T. Loftsson, „Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration”, *J. Control. Rel.* **102**, 255-262 (2005).
 195. M Duan, N. Zhao, Í. B. Össurardóttir, T. Thorsteinnsson and T. Loftsson, „Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: formation of aggregates and higher-order complexes”, *Int. J. Pharm.* **297**, 213-222 (2005).
 196. T. Loftsson, P. Jarho, M. Másson and Tomi Järvinen, „Cyclodextrins in drug delivery”, *Expert Opin. Drug Deliv.*, **2**, 335-351 (2005).
 197. M. Másson, B. V. Sigurdardóttir, K. Matthíasson, T. Loftsson, „Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical considerations”, *Chem. Pharm. Bull.* **53**, 958-964 (2005).
 198. T. Loftsson, T. Thorsteinnsson and M. Másson, „Hydrolysis kinetics and QSAR investigation of soft antimicrobial agents”, *J. Pharm. Pharmacol.* **57**, 721-727 (2005).
 199. T. Loftsson, D. Hreinsdóttir and M. Másson, „Evaluation of cyclodextrin solubilization of drugs”, *Int. J. Pharm.* **302**, 18-28 (2005).

200. H.H. Sigurdsson, T. Loftsson and C.-M. Lehr, „Assessment of mucoadhesion by a resonant mirror biosensor”, #519, *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.*, 32 (2005), Controlled Release Society, Minneapolis, USA.
201. O. Dale, T. Nilsen, T. Loftsson, H. Hjorth Tønnesen, P. Klepstad, S. Kaasa, T. Holand and Per G. Djupesland, „Unexpected discrepancy between bioavailability and pharmacodynamic effect in the CNS when comparing two nasal sprays”, *J. Pharm. Pharmacol.*, **58**, 1311-1318 (2006).
202. T. Loftsson, „Cyclodextrin complexation and drug permeation through biological membranes”, *Pharma*, **1**(1), 70-74 (2005).
203. M. Másson, T. Benediktsson, T. Andrésón, T. Thorsteinsson and T. Loftsson, „Investigation of soft long chain quaternary ammonium compounds as co-factors to enhance in-vitro gene delivery”, *Pharmazie*, **61**, 564-566 (2006).
204. T. Loftsson, F. Konráðsdóttir and M. Másson, „Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes”, *Pharmazie*, **61**, 83-89 (2006).
205. T. Loftsson and D. Hreinsdóttir, „Determination of aqueous solubility by heating and equilibration: a technical note” *AAPS PharmSciTech*, **7**(1) (2006) (<http://www.aapspharmsciotech.org>).
206. H.H. Sigurdsson, F. Konráðsdóttir, T. Loftsson and E. Stefánsson, „Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye”, *Acta Ophthalmol. Scand.* **85**, 598-602 (2007).
207. H.H. Sigurdsson, T. Loftsson and C.-M. Lehr, „Assessment of mucoadhesion by a resonant mirror biosensor”, *Int. J. Pharm.* **325**, 75-81 (2006).
208. S.H. Hardarson, H.H. Sigurdsson, G.E. Níelsdóttur, J. Valgeirsson, T. Loftsson and E. Stefánsson, „Ocular powder: dry topical formulations of timolol are well tolerated in rabbits” *Journal of Ocular Pharmacology and Therapeutic*, **22**, 340-346 (2006).
209. T. Loftsson, F. Konráðsdóttir and M. Másson, „Development and evaluation of an artificial membrane for determination of drug availability”, *Int. J. Pharm.* **326**, 60-68 (2006).
210. T. Loftsson, D. Hreinsdóttir and M. Másson, „The complexation efficiency”, *J. Incl. Phenom. Macroc. Chem.* **57**, 545-552 (2007).
211. T. Loftsson, H. H. Sigurdsson, D. Hreinsdóttir, F. Konráðsdóttir and E. Stefánsson, „Dexamethasone delivery to posterior segment of the eye”, *J. Incl. Phenom. Macroc. Chem.* **57**, 585-589 (2007).
212. T. Loftsson, F. Konráðsdóttir and M. Másson, „Development of octanol membranes for drug screening” *J. Incl. Phenom. Macroc. Chem.* **57**, 613-617 (2007).
213. M Másson, F. J. Karlsson, M. Valdimarsdóttir, K. Magnúsdóttir, T. Loftsson, „Cyclodextrins and the liquid-liquid phase distribution of progesterone, estrone and prednicarbate” *J. Incl. Phenom. Macroc. Chem.* **57**, 481-487 (2007).

214. M. E. Brewster, Claire Mackie, Ann Lampo, M. Noppe and T. Loftsson, „The use of solubilizing excipients and approaches to generate toxicology vehicles for contemporary drug pipelines”, Chapter 8 in *Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics* (P. Augustijns and M. E. Brewster, Eds.), pp. 221-256, American Association of Pharmaceutical Scientists, Springer, New York 2007.
215. T. Loftsson and E. Stefánsson, „Cyclodextrins in ocular drug delivery: theoretical basis with dexamethasone as a sample drug”, *J. Drug Del. Sci. Tech.*, **17**, 3-9 (2007).
216. T. Loftsson, D. Hreinsdóttir, E. Stefánsson, „Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops”, *J. Pharm. Pharmacol.*, **59**, 629-635 (2007).
217. E. Stefánsson and T. Loftsson, „The Stokes-Einstein equation and the physiological effects of vitreous surgery”, *Acta Ophthalmol. Scand.*, **84**, 718-719 (2006).
218. T. Loftsson and D. Duchêne, „Historical perspective. Cyclodextrins and their pharmaceutical applications”, *Int. J. Pharm.*, **329**, 1-11 (2007).
219. J. Iwai, N. Ogawa, H. Nagase, T. Endo, T. Loftsson and H. Ueda, „Effects of various cyclodextrins on the stability of freeze-dried lactate dehydrogenase”, *J. Pharm. Sci.*, **96**, 3140-3143 (2007).
220. M. E. Brewster, M. Noppe, J. Peeters and T. Loftsson, „Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins”, *Int. J. Pharm.* **342**, 250-253 (2007).
221. M. E. Brewster, R. Vandecruys, J. Peeters, P. Neeskens, G. Verreck and T. Loftsson, „Comparative interaction of 2-hydroxypropyl- β -cyclodextrin and sulfobutylether- β -cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions”, *Eur. J. Pharm. Sci.* **34**, 94-103 (2008).
222. Ö. V. Rúnarsson, J. Holappa, T. Nevalainen, M. Hjálmarsdóttir, T. Järvinen, T. Loftsson, J. M. Einarsson, S. Jónsdóttir, M. Valdimarsdóttir and M. Másson, „Antibacterial activity of methylated chitosan and chito oligomer derivatives: synthesis and structure activity relationships”, *Eur. Polym. J.*, **43**, 2660-2671 (2007).
223. Thorsteinn Loftsson, „Aquavitae. Áhrif vatns á lyfjaþróun”. In *Vísindin heilla - Sigmundur Guðbjarnason 75 ára*, Guðmundur G. Haraldsson (Ed.), Háskólaútgáfan, Reykjavík, 2006, pp. 376-388.
224. T. Loftsson, S. Byskov Vogensen, M. E. Brewster, F. Konráðsdóttir, „Effects of cyclodextrins on drug delivery through biological membranes”, *J. Pharm. Sci.*, **96**, 2532-2546 (2007).
225. M. A. Tomren, M. Másson, T. Loftsson, H. Hjorth Tønnesen, „Studies on curcumin and curcuminoids. XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin”, *Int. J. Pharm.*, **338**, 27-34 (2007).
226. M. E. Brewster and T. Loftsson, „Cyclodextrins as pharmaceutical solubilizers”, *Adv. Drug Deliv. Rev.*, **59**, 645-666 (2007).

227. T. Loftsson and M. E. Brewster, „ Physicochemical properties of water and its effect on drug delivery. A commentary”, *Int. J. Pharm.* **354**, 248–254 (2008).
228. T. Loftsson, H. H. Sigurðsson, F. Konráðsdóttir, S. Gísladóttir, P. Jansook and E. Stefánsson, „Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations”, *Pharmazie*, **63**, 171-179 (2008).
229. T. Loftsson, S. B. Vogensen, C. Desbos and P. Jansook, „Carvedilol: Solubilization and Cyclodextrin Complexation. A Technical Note”, *AAPS PharmSciTech* in print (2008).
230. Einar Stefánsson and Thorsteinn Loftsson, “Microspheres and nanotechnology for drug delivery”, Chapter 15 in *Retinal Pharmacotherapy* (Q. D. Nguyen, E. B. Rodrigues, M. E. Farah and W. F. Mieler, Eds.), Elsevier, UK (in print).
231. Marcus E. Brewster, Jef Peeters, Geert Verreck and Thorsteinn Loftsson, „Hydrophilic cyclodextrins to support and stabilize supersaturated drug solutions”, manuscript.
232. T. Loftsson and E. Stefánsson, „Enalaprilat and enalapril maleate eye drops”, manuscript.
233. F. Konráðsdóttir and T. Loftsson, „Fish skin as a model membrane: structure and characteristics”, *J. Pharm. Pharmacol.* (in print).
234. P. Jansook and T. Loftsson, „ γ CD/HP γ CD: synergistic solubilization”. *Int. J. Pharm.* (in print).
235. T. Loftsson, „Cyclodextrin-based drug delivery: the unstirred water layer”, *APGI Newsletter* (in print).